

GenepowerRx launches AI platform for big data analytics and drug discovery

05 January 2024 | News

Drs Kalyan Uppaluri and Hima J Challa, founders of K&H clinics and pioneers behind GeneConnectRx, unveiled the platform, marking a new era in medical research



Uppaluri K&H Personalized Medicine Clinic has unveiled GeneConnectRx, an innovative artificial intelligence (AI) platform launched by GenepowerRx, the diagnostic wing of K&H clinic. This revolutionary step in personalised medicine marks a paradigm shift, empowering healthcare providers to customize treatments based on individual genetic makeup.

The launch ceremony at the startup's Hyderabad headquarters welcomed luminaries and industry leaders, underscoring the transformative potential of GeneConnectRx.

The esteemed guests included Padma Bhushan Dr D Nageshwar Reddy, Chairman and Chief of Gastroenterology at AIG Hospitals; Penmetsa Venkata Subba Raju, Vice Chairman of AIG Hospitals; and Prof. Ch Mohan Rao, CSIR - Distinguished Scientist and Former Director, Centre for Cellular & Molecular Biology (CCMB).

GeneConnectRx represents the collaborative efforts of a multidisciplinary team comprising computational scientists, molecular biologists, bioinformaticians, and chemoinformaticians. Over two years, this team identified drug targets for complex medical conditions.

Dr Nageshwar Reddy commented, "Personalised medicine must become standard practice in every hospital. Focused research in this space is crucial to provide accurate, effective, and affordable personalized medicine products to all individuals."

"GeneConnectRx is poised to revolutionise AI-based drug discovery, propelling precision medicine. Our ongoing efforts focus on validating drug targets for Brain Cancer, Monogenic Diabetes, Parkinson's disease, High Cholesterol, and Autism. Our process patent application reflects our dedication to innovation," expressed Dr Kalyan Uppaluri from GenepowerRx.

"Our collaboration with AIG Hospitals has resulted in groundbreaking initiatives like AIG's pharmacogenomics study. GeneConnectRx integrates internal data, global resources, and cutting-edge models to forecast potential molecules for revolutionary drug discovery," highlighted Dr Hima Challa.